Shares of Wyeth are off more than 10% this morning and Elan is down more than 30% as the market frets over the future of an Alzheimer’s drug the companies are developing.
Yesterday, the companies released the full results of a mid-stage trial that failed to show an overall benefit in cognitive function for Alzheimer’s patients [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment